IndraLab

Statements

KRAS methylates FHIT. 3 / 3
| 3
sparser
"Overall, advanced tumor stage (97%), metastatic disease (100%), moderately to poorly differentiated tumors (84%) and presence of lymphatic invasion (92%) were more frequently observed in tumors with mutated Kras (codon 12) and methylated RASSF1A, FHIT and MGMT genes."
23573237
sparser
"Overall, tumor stage 3, moderately differentiated tumors, presence of lymphatic invasion and absence of metastasis was more frequently observed in tumors with mutated Kras and/or methylated RASSF1A, FHIT and MGMT genes."
23573237
sparser
"Taken together, the data demonstrated that tumor stage 3, moderately differentiated tumors, presence of lymphatic invasion and absence of metastasis were more frequently observed in tumors with mutated Kras and methylated RASSF1A, FHIT and MGMT genes."
23573237